JP2015155425A5 - - Google Patents

Download PDF

Info

Publication number
JP2015155425A5
JP2015155425A5 JP2015071973A JP2015071973A JP2015155425A5 JP 2015155425 A5 JP2015155425 A5 JP 2015155425A5 JP 2015071973 A JP2015071973 A JP 2015071973A JP 2015071973 A JP2015071973 A JP 2015071973A JP 2015155425 A5 JP2015155425 A5 JP 2015155425A5
Authority
JP
Japan
Prior art keywords
chco
oso
hydrogen
alkyl
hydroxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015071973A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015155425A (ja
JP6122055B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2015155425A publication Critical patent/JP2015155425A/ja
Publication of JP2015155425A5 publication Critical patent/JP2015155425A5/ja
Application granted granted Critical
Publication of JP6122055B2 publication Critical patent/JP6122055B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015071973A 2007-01-22 2015-03-31 核内受容体結合剤 Active JP6122055B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US88147607P 2007-01-22 2007-01-22
US60/881,476 2007-01-22
US90775407P 2007-04-16 2007-04-16
US60/907,754 2007-04-16

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2013271202A Division JP5726998B2 (ja) 2007-01-22 2013-12-27 核内受容体結合剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016245320A Division JP2017075170A (ja) 2007-01-22 2016-12-19 核内受容体結合剤

Publications (3)

Publication Number Publication Date
JP2015155425A JP2015155425A (ja) 2015-08-27
JP2015155425A5 true JP2015155425A5 (OSRAM) 2015-10-08
JP6122055B2 JP6122055B2 (ja) 2017-04-26

Family

ID=39645049

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2009546440A Expired - Fee Related JP5484914B2 (ja) 2007-01-22 2008-01-22 核内受容体結合剤
JP2013271202A Expired - Fee Related JP5726998B2 (ja) 2007-01-22 2013-12-27 核内受容体結合剤
JP2015071973A Active JP6122055B2 (ja) 2007-01-22 2015-03-31 核内受容体結合剤
JP2016245320A Pending JP2017075170A (ja) 2007-01-22 2016-12-19 核内受容体結合剤

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2009546440A Expired - Fee Related JP5484914B2 (ja) 2007-01-22 2008-01-22 核内受容体結合剤
JP2013271202A Expired - Fee Related JP5726998B2 (ja) 2007-01-22 2013-12-27 核内受容体結合剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016245320A Pending JP2017075170A (ja) 2007-01-22 2016-12-19 核内受容体結合剤

Country Status (15)

Country Link
US (1) US9078888B2 (OSRAM)
EP (2) EP2106212B1 (OSRAM)
JP (4) JP5484914B2 (OSRAM)
KR (3) KR101638035B1 (OSRAM)
CN (2) CN103432133B (OSRAM)
AU (1) AU2008209581B2 (OSRAM)
BR (1) BRPI0806371A2 (OSRAM)
CA (1) CA2676066C (OSRAM)
EA (3) EA026578B1 (OSRAM)
ES (1) ES2475193T3 (OSRAM)
IL (2) IL199996A (OSRAM)
IS (1) IS8842A (OSRAM)
MX (1) MX2009007831A (OSRAM)
NO (1) NO20092822L (OSRAM)
WO (1) WO2008091555A2 (OSRAM)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
EA026578B1 (ru) * 2007-01-22 2017-04-28 ДЖиТиЭкс, ИНК. Вещества, связывающие ядерные рецепторы
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US20110136842A1 (en) * 2008-08-06 2011-06-09 Duffy Joseph L Substituted Dihydroisoquinolinone and Isoquinolinedione Derivatives as Calcium Channel Blockers
SG172154A1 (en) * 2008-12-16 2011-07-28 Sirtris Pharmaceuticals Inc Phthalazinone and related analogs as sirtuin modulators
EP2416797A4 (en) * 2009-04-10 2013-04-24 Amylin Pharmaceuticals Llc AMYLINAGONIST COMPOUNDS FOR OXYGEN ANIMAL MICE
CN101928245A (zh) * 2010-09-02 2010-12-29 西安交通大学 8-羟基或甲氧基-2-芳基-1-异喹啉酮及其合成方法和用途
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN102875466A (zh) * 2012-04-23 2013-01-16 中国药科大学 异喹啉酮衍生物,其制备方法及其医药用途
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
JP6226978B2 (ja) 2012-07-13 2017-11-08 ジーティーエックス・インコーポレイテッド 選択的アンドロゲン受容体モジュレーター（ｓａｒｍ）によりアンドロゲン受容体（ａｒ）陽性乳癌を処置する方法
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
JP6401702B2 (ja) 2012-09-07 2018-10-10 ザ・ガバナーズ・オブ・ザ・ユニバーシティー オブ・アルバータ 炎症性肝疾患の診断のための方法および組成物
WO2014039820A1 (en) * 2012-09-07 2014-03-13 Gtx, Inc. Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2014063105A1 (en) * 2012-10-19 2014-04-24 Celus Pharmaceuticals, Inc. Vitamin d analogues for the treatment of a neurological disorder
EP3041465B1 (en) 2013-09-06 2020-11-11 The University Of Montana Method of reducing neuronal cell death with haloalkylamines
SG10201902074UA (en) 2013-10-04 2019-04-29 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20150133547A1 (en) * 2013-11-08 2015-05-14 Richard W. Hertle Method and composition for treating glaucoma
US9095505B2 (en) 2013-11-08 2015-08-04 Rbg Group, Ltd. Pyrethroids for treatment of ocular movement disorders
CN113616656B (zh) 2014-03-19 2023-02-17 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
LT3126330T (lt) 2014-04-04 2019-04-25 Pfizer Inc. Bicikliniai kondensuoti heteroarilo arba arilo junginiai, ir jų panaudojimas kaip irak4 inhibitorių
MX2016015873A (es) * 2014-06-03 2017-03-27 Hoffmann La Roche Peptidos como agonistas de oxitocina.
CR20160562A (es) * 2014-06-06 2017-01-06 Hoffmann La Roche Péptidos como agonistas de la oxitocina
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2016322552B2 (en) 2015-09-14 2021-03-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
CN105294561B (zh) * 2015-11-27 2018-03-30 中国药科大学 一种异喹啉及其制备方法和应用
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
TW202104207A (zh) * 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
WO2021155195A1 (en) * 2020-01-29 2021-08-05 Georgetown University Compositions and methods for treating neurodegenerative, neurodevelopmental, myodegenerative, and lysosomal storage disorders
WO2022006470A1 (en) 2020-07-01 2022-01-06 Vanderbilt University Methods of treatment for a kidney disease
CN115925624B (zh) * 2022-12-12 2025-06-27 浙江工业大学 N-芳基-多元环并[c]-2-吡啶酮衍生物、合成方法及其应用
WO2024199524A1 (zh) * 2023-03-31 2024-10-03 江苏星盛新辉医药有限公司 作为pkmyt1抑制剂的化合物

Family Cites Families (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2848356A (en) * 1954-08-30 1958-08-19 Phillips Petroleum Co Fungicides, their preparation and use
CA1285951C (en) 1985-10-28 1991-07-09 Raj N. Misra Naphthalenyl- and quinolinyl-amino substituted phenols
US4921941A (en) 1987-07-01 1990-05-01 Schering Corporation Orally active antiandrogens
KR890011876A (ko) 1988-01-27 1989-08-23 메이 앤드 베이커 리미팃드 신규한 이소퀴놀린 유도체 그의 제조방법 및 그를 함유하는 제약학적 조성물
US5177075A (en) 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
US4942163A (en) 1989-03-07 1990-07-17 E. I. Du Pont De Nemours And Company 1(2H)-isoquinolinones and 1-isoquinolineamines as cancer chemotherapeutic agents
US5112869A (en) * 1989-04-04 1992-05-12 Sloan-Kettering Institute For Cancer Research Substituted 1-phenylnaphthalenes
KR920008026A (ko) 1990-10-24 1992-05-27 오노 화아마슈티칼 캄파니 리미팃드 이소퀴놀리논 유도체 또는 이의 무독성 산부가염 또는 이의 수화물, 이의 제조방법 및 이를 포함하는 약제 조성물
EP0502575A1 (en) 1991-03-06 1992-09-09 Merck & Co. Inc. Substituted 1-(2H)-isoquinolinones
ATE198328T1 (de) 1992-09-28 2001-01-15 Hoechst Ag Antiarrhythmische und cardioprotektive substituierte 1(2h)-isochinoline, verfahren zu deren herstellung, diese enthaltende arzneimittel und ihre anwendung für die herstellung eines arzneimittels zur behandlung von herzinsuffizienzen
DE4345266C2 (de) 1993-10-04 1996-12-19 Luitpold Pharma Gmbh Heterocyclische Carbamate, Verfahren zu ihrer Herstellung und Arzneimittel
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5719144A (en) 1995-02-22 1998-02-17 Merck & Co., Inc. Fibrinogen receptor antagonists
IT1307327B1 (it) 1995-09-12 2001-10-30 Smithkline Beecham Spa Derivati idroisochinolinici sostituiti
AU1730497A (en) 1996-02-17 1997-09-02 Agrevo Uk Limited Fungicidal 1,2,4-oxadiazoles and analogues
SE9600769D0 (sv) 1996-02-28 1996-02-28 Astra Ab Compounds useful as analgesic
BR9714189A (pt) 1996-12-27 2000-02-29 Hoechst Marion Roussel Inc N-(piridinilamino) isoindolinas e compostos relacionados
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
WO1998038168A1 (en) 1997-02-27 1998-09-03 Tanabe Seiyaku Co., Ltd. Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
JPH10259176A (ja) 1997-03-17 1998-09-29 Japan Tobacco Inc 血管新生阻害作用を有する新規アミド誘導体及びその用途
CN1198614C (zh) 1997-05-13 2005-04-27 奥科特默股份有限公司 pADPRT抑制剂在用于制备治疗炎症和炎性疾病的药物中的方法
US20020022636A1 (en) * 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
KR20010083092A (ko) 1998-07-06 2001-08-31 스티븐 비. 데이비스 이중 안지오텐신 엔도텔린 수용체 길항제로서의 비페닐술폰아미드
JP2000072675A (ja) 1998-08-26 2000-03-07 Tanabe Seiyaku Co Ltd 医薬組成物
AU1199600A (en) 1998-10-02 2000-04-26 Board Of Trustees Of The University Of Illinois, The Estrogen receptor ligands
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6593322B1 (en) 1999-03-17 2003-07-15 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6436923B1 (en) 1999-03-17 2002-08-20 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
JP2003506355A (ja) 1999-08-03 2003-02-18 アボット・ラボラトリーズ カリウムチャンネル開放剤
WO2001022960A1 (en) 1999-09-30 2001-04-05 Charlotte-Mecklenburg Hospital Authority Doing Business As Carolinas Medical Center Treatment of carbon monoxide poisoning
CO5271709A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
JP4331913B2 (ja) 2000-02-14 2009-09-16 メルク エンド カムパニー インコーポレーテッド エストロゲンレセプターモデュレーター
PE20011077A1 (es) 2000-03-01 2001-12-12 Akzo Nobel Nv Derivados de cromano que tiene afinidad por receptores de estrogenos
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
JP2004506712A (ja) 2000-08-23 2004-03-04 アクゾ・ノベル・エヌ・ベー 医療に使用するための１０−アリール−１１Ｈ−ベンゾ［ｂ］フルオレン誘導体および類似体
EP1322619B1 (en) 2000-09-20 2008-01-23 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
CA2321406A1 (en) 2000-09-29 2002-03-29 The Regents Of The University Of California Restoration of perturbed barrier function by application of antiandrogens
JP2004511501A (ja) 2000-10-19 2004-04-15 メルク　エンド　カムパニー　インコーポレーテッド エストロゲン受容体モジュレーター
CA2428019C (en) 2000-11-27 2010-09-21 Merck & Co., Inc. Estrogen receptor modulators
EP1341765A1 (en) 2000-12-07 2003-09-10 AstraZeneca AB Therapeutic compounds
EP1341768A1 (en) 2000-12-07 2003-09-10 AstraZeneca AB Therapeutic benzimidazole compounds
US7045539B2 (en) 2000-12-22 2006-05-16 Astrazeneca Ab Therapeutic benzoxazole compounds
WO2002058639A2 (en) 2001-01-23 2002-08-01 Merck & Co., Inc. Pyranoflavonoid compounds and their use as estrogen receptor modulators
WO2002072561A1 (en) 2001-01-26 2002-09-19 Smithkline Beecham Corporation Piperazinyltriazines as estrogen receptor modulators
HUP0400058A2 (hu) 2001-02-02 2004-04-28 Takeda Chemical Industries, Ltd. Kondenzált heterogyűrűs vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
US20040171006A1 (en) * 2001-04-27 2004-09-02 Yonghong Xiao Regulation of human prostaglandin-f synthase 1-like protein
ES2282410T3 (es) 2001-05-08 2007-10-16 Kudos Pharmaceuticals Limited Derivados de isoquinolinona como inhibidores de parp.
WO2002091993A2 (en) 2001-05-10 2002-11-21 Merck & Co., Inc. Estrogen receptor modulators
EP1396488A1 (en) 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
EP1392287B8 (en) * 2001-05-25 2007-01-10 Schering Corporation Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease
US20030119800A1 (en) 2001-06-18 2003-06-26 Manolagas Stavros C. Bone anabolic compounds and methods of use
ES2274986T3 (es) 2001-08-01 2007-06-01 MERCK & CO., INC. Derivados de benzimidazo 4,5-f/isoquinolinona.
WO2003015761A1 (en) 2001-08-13 2003-02-27 Merck & Co., Inc. Selective estrogen receptor modulators
SE0103644D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic isoquinoline compounds
EP1478631A1 (en) 2001-11-28 2004-11-24 AstraZeneca AB Therapeutic compounds
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
EP1454898A4 (en) 2001-12-13 2006-12-13 Ajinomoto Kk NEW PHENYL ALANIDE DERIVATIVES
US6960607B2 (en) 2001-12-13 2005-11-01 Wyeth Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents
US6903238B2 (en) 2001-12-13 2005-06-07 Wyeth Substituted indenones as estrogenic agents
TWI306450B (en) 2001-12-13 2009-02-21 Wyeth Corp Substituted phenyl naphthalenes as estrogenic agents
TW200301107A (en) 2001-12-13 2003-07-01 Wyeth Corp Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents
US6774248B2 (en) 2001-12-18 2004-08-10 Wyeth Substituted 2-phenyl benzofurans as estrogenic agents
US7015219B2 (en) 2001-12-19 2006-03-21 Bristol-Myers Squibb Company 3-aryl-hydroxybenzoxazines and 3, 4-dihydro-3-aryl-hydroxybenzoxazines as selective estrogen receptor beta modulators
TW200408385A (en) 2001-12-21 2004-06-01 Akzo Nobel Nv Tetrahydrobenzfluorene derivatives
US6835745B2 (en) 2002-01-15 2004-12-28 Wyeth Phenyl substituted thiophenes as estrogenic agents
US6630508B1 (en) 2002-02-11 2003-10-07 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor β agonists
US7402595B2 (en) 2002-02-13 2008-07-22 Takeda Pharmaceutical Company Limited JNK inhibitor
US7214693B2 (en) 2002-10-15 2007-05-08 University Of Tennessee Research Foundation Heterocyclic selective androgen receptor modulators and methods of use thereof
AU2003212856A1 (en) 2002-03-01 2003-09-16 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
US7381730B2 (en) 2002-03-15 2008-06-03 Bristol-Myers Squibb Company 3-arylquinazoline derivatives as selective estrogen receptor beta modulators
US7138426B2 (en) 2002-04-24 2006-11-21 Merck & Co., Inc. Estrogen receptor modulators
US20030220377A1 (en) 2002-05-08 2003-11-27 Richard Chesworth Indole compounds and their use as estrogen agonists/antagonists
CA2489906A1 (en) * 2002-06-06 2003-12-18 University Of Rochester Androgen receptor coregulators
DE10230381A1 (de) 2002-07-05 2004-01-22 Institut für Medizintechnologie Magdeburg GmbH, IMTM Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen
WO2004006906A2 (en) 2002-07-15 2004-01-22 Combinatorx, Incorporated Methods for the treatment of neoplasms
US6893191B2 (en) 2002-07-19 2005-05-17 Creative Pultrusions, Inc. Wale and retaining wall system
MXPA05000983A (es) * 2002-07-24 2005-08-18 Kyorin Seiyaku Kk Derivados de 4-(aril substituido)-5-hidroxiisoquinolinona.
WO2004014378A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
JPWO2004024694A1 (ja) 2002-09-10 2006-01-05 杏林製薬株式会社 ４−置換アリール−５−ヒドロキシイソキノリノン誘導体
US20060039974A1 (en) 2002-09-11 2006-02-23 Takeda Pharmaceutical Company Limited Sustained release preparation
WO2004026290A1 (en) 2002-09-19 2004-04-01 Merck & Co., Inc. Method for treating depression and/or anxiety
MXPA05003054A (es) 2002-09-20 2005-05-27 Pfizer Prod Inc Ligandos de amida y sulfonamida para el receptor de estrogenos.
US7501412B2 (en) 2002-11-22 2009-03-10 Mitsubishi Tanabe Pharma Corporation Isoquinoline compounds and medicinal use thereof
AU2003301020A1 (en) 2002-12-20 2004-07-22 Sankyo Company, Limited Isoquinolinone derivatives and their use as therapeutic agents
US7199110B2 (en) 2002-12-30 2007-04-03 Purdue Research Foundation Method of treatment for spinal cord injury
WO2004073612A2 (en) 2003-02-13 2004-09-02 Merck & Co. Inc. Estrogen receptor modulators
WO2004083184A1 (ja) 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited 受容体拮抗剤
US20060111318A1 (en) 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
WO2004094400A2 (en) 2003-04-21 2004-11-04 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
WO2004094401A1 (en) 2003-04-21 2004-11-04 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
DE602004004124T2 (de) 2003-05-16 2007-04-26 Wyeth Aryl-carbaldehyd oxime-verbindungen und deren verwendung als oestrogenwirksame substanzen
CL2004000985A1 (es) 2003-05-16 2005-01-14 Wyeth Corp Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc
US7250440B2 (en) 2003-08-12 2007-07-31 Wyeth (Hydroxyphenyl)-1H-indole-3-carbaldehyde oxime derivatives as estrogenic agents
WO2005030727A1 (en) 2003-09-23 2005-04-07 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
CN1856476A (zh) 2003-09-23 2006-11-01 默克公司 异喹啉酮钾通道抑制剂
US7741322B2 (en) 2003-09-23 2010-06-22 Merck Sharp & Dohme Corp. Isoquinolinone potassium channel inhibitors
CN1863789B (zh) 2003-10-03 2010-06-09 博尔托拉制药公司 取代的异喹啉酮
ATE534404T1 (de) 2003-10-03 2011-12-15 Takeda Pharmaceutical Dipeptidylpeptidase-iv-inhibitoren zur behandlung von diabetes-patienten mit sekundärversagen durch sulfonylharnstoffe
JP2007512344A (ja) 2003-11-24 2007-05-17 メルク　エンド　カムパニー　インコーポレーテッド エストロゲン受容体調節剤
WO2005097141A2 (en) 2003-11-24 2005-10-20 Merck & Co., Inc. Estrogen receptor modulators
EP1689410B1 (en) 2003-11-26 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Prevention and treatment of hypertensive heart diseases by the selective estrogens 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol and 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol
AU2005212092B2 (en) * 2004-02-13 2011-01-20 Msd K.K. Fused-ring 4-oxopyrimidine derivative
US7157492B2 (en) 2004-02-26 2007-01-02 Wyeth Dibenzo chromene derivatives and their use as ERβ selective ligands
WO2005099700A1 (en) 2004-04-06 2005-10-27 Merck & Co., Inc. Methods for the treatment of hypertension
BRPI0510639A (pt) 2004-05-04 2007-11-13 Acadia Pharm Inc composto ou um sal ou uma pró-droga farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos de tratar ou prevenir distúrbios, de terapia de reposição hormonal, de abaixar nìveis de colesterol, triglicerìdeos ou ldl, de tratar cognição prejudicada ou prover neuroproteção, de prevenir concepção, de modular ou agonizar especificamente um ou mais receptores de estrogênio e, uso de um composto
CN1968960A (zh) 2004-06-10 2007-05-23 默克公司 雌激素受体调节剂
WO2006009912A1 (en) 2004-06-23 2006-01-26 Merck & Co., Inc. Estrogen receptor modulators
JP2008505079A (ja) 2004-06-30 2008-02-21 メルク　エンド　カムパニー　インコーポレーテッド エストロゲン受容体調節剤
EP1761513A1 (en) 2004-07-01 2007-03-14 Wyeth Tetracyclic compounds as estrogen ligands
DE102004039921A1 (de) 2004-08-18 2006-03-02 Henkel Kgaa Klarspülhaltige Wasch- und Reinigungsmittel mit schwefelhaltigen Aminosäuren
CN101072564A (zh) 2004-08-26 2007-11-14 恩希赛弗制药公司 内皮缩血管肽a受体(eta)拮抗剂与磷酸二酯酶5(pde5)抑制剂的联合及其用途
US20060205733A1 (en) 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
RU2007106870A (ru) 2004-09-07 2008-10-20 Вайет (Us) 6Н-[1]БЕНЗОПИРАНО[4,3-b]ХИНОЛИНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЭСТРОГЕННЫХ АГЕНТОВ
ES2361031T3 (es) 2004-10-18 2011-06-13 Eli Lilly And Company Benzopiranos sustituidos como agonistas selectivos del receptor beta de estrógenos.
AR051597A1 (es) 2004-11-01 2007-01-24 Merck & Co Inc Moduladores de los receptores de estrogeno
US7511152B2 (en) 2004-12-09 2009-03-31 Merck & Co., Inc. Estrogen receptor modulators
RU2007129150A (ru) 2004-12-31 2009-02-10 Авентис Фармасьютикалз Инк. (Us) Применение ряда фенилнафтильных соединений, которые не проявляют значительной аффинности в отношениях эстрогеновых рецепторов (er)
WO2006081152A2 (en) 2005-01-24 2006-08-03 Merck & Co., Inc. Estrogen receptor modulators
EP1853578A1 (en) 2005-02-15 2007-11-14 Eli Lilly And Company Substituted tetralins as selective estrogen receptor-beta agonists
KR20070103456A (ko) 2005-02-16 2007-10-23 와이어쓰 방사선- 또는 화학요법-유발 점막염 및 방사선 방광염용에스트로겐 수용체-β 선택적 아고니스트의 용도
US7482029B2 (en) 2005-04-01 2009-01-27 Bionovo, Inc. Composition for treatment of menopause
CN101184395A (zh) 2005-04-06 2008-05-21 Irm责任有限公司 包含二芳基胺的化合物和组合物及其作为类固醇激素核受体调节剂的用途
US9763961B2 (en) 2005-04-13 2017-09-19 City Of Hope Compositions that modulate the activity of estrogen receptors and estrogen-related receptors and methods for use
US7456188B1 (en) * 2005-04-28 2008-11-25 Bristol-Myers Squibb Company C-5 substituted quinazolinone derivatives as selective estrogen receptor beta modulators
US20070021495A1 (en) 2005-07-25 2007-01-25 Katzenellenbogen John A Sulfonamides as selective estrogen receptor
NI200800025A (es) * 2005-07-26 2009-03-03 Derivados de isoquinolona sustituidos con piperidinilo en calidad de inhibidores de rho-quinasa
ATE517871T1 (de) 2005-10-05 2011-08-15 Merck Sharp & Dohme Östrogenrezeptormodulatoren
WO2007053353A2 (en) 2005-10-28 2007-05-10 Wyeth Pyrrolo[2,3-f] and [3,2-f]isoquinolinone derivatives as 5-hydroxytryptamine-6 ligands
US20070197488A1 (en) 2005-11-29 2007-08-23 Olaf Peters Prodrugs of ERbeta-selective substances, process for their production, and pharmaceutical compositions that contain these compounds
EP1981539B1 (en) * 2006-02-09 2014-07-23 Amgen Research (Munich) GmbH Treatment of metastatic breast cancer
WO2007093364A1 (en) 2006-02-15 2007-08-23 Sanofi-Aventis Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
CA2636617A1 (en) 2006-02-15 2007-08-23 Lothar Schwink Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
EP1990335A4 (en) * 2006-03-02 2009-11-11 Astellas Pharma Inc 17-BETA-HSD-type-5 INHIBITOR
US8481529B2 (en) 2006-05-16 2013-07-09 The Arizona Board Of Regents On Behalf Of The University Of Arizona Combination cancer chemotherapy
JP2009541310A (ja) 2006-06-19 2009-11-26 アストラゼネカ・アクチエボラーグ イソキノリン誘導体およびサイトカイン仲介疾患の阻害剤としてのそれらの使用
US8318941B2 (en) * 2006-07-06 2012-11-27 Bristol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
JP2009545605A (ja) 2006-08-02 2009-12-24 ユニバーシティ オブ サザン カリフォルニア フィトエストロゲン製剤およびその使用
US8058243B2 (en) * 2006-10-13 2011-11-15 Hsc Research And Development Limited Partnership Method for treating a brain cancer with ifenprodil
EA026578B1 (ru) * 2007-01-22 2017-04-28 ДЖиТиЭкс, ИНК. Вещества, связывающие ядерные рецепторы
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
GB0722779D0 (en) * 2007-11-20 2008-01-02 Sterix Ltd Compound
US20100029734A1 (en) * 2008-05-06 2010-02-04 Ore Pharmaceuticals Inc. Methods for breast cancer screening and treatment

Similar Documents

Publication Publication Date Title
JP2015155425A5 (OSRAM)
JP2016503793A5 (OSRAM)
JP2016500661A5 (OSRAM)
JP2009506119A5 (OSRAM)
JP2013525494A5 (OSRAM)
JP2017536395A5 (OSRAM)
JP2013545785A5 (OSRAM)
JP2014503525A5 (OSRAM)
JP2013542261A5 (OSRAM)
JP2014515351A5 (OSRAM)
JP2016503797A5 (OSRAM)
JP2014097964A5 (OSRAM)
JP2012092103A5 (OSRAM)
JP2014511892A5 (OSRAM)
JP2018534348A5 (OSRAM)
JP2013523802A5 (OSRAM)
JP2016512505A5 (OSRAM)
PH12015502011A1 (en) Substituted aromatic compounds and related method for the treatment of fibrosis
JP2014511891A5 (OSRAM)
JP2019510082A5 (OSRAM)
JP2006518328A5 (OSRAM)
RU2014136394A (ru) Морфолиноалкилфумаратные соединения, фармацевтические композиции и способы применения
JP2020502047A5 (OSRAM)
JP2017508817A5 (OSRAM)
JP2013209405A5 (OSRAM)